Nasdaq · Healthcare

Taysha Gene Therapies, Inc. (TSHA)

As-reported financials and recent SEC filings for Taysha Gene Therapies, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$9.8M

Net income

$-109.0M

Net margin

—

Diluted EPS

$-0.34

ROE

-44.1%

P/E (TTM)

—

Market cap

—

Debt / equity

0.2×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$9.8M	$8.3M	$15.5M	$2.5M	—
Gross profit	—	—	—	—	—
Operating income	$-110.5M	$-91.5M	$-72.4M	$-162.4M	$-173.3M
Net income	$-109.0M	$-89.3M	$-111.6M	$-166.0M	$-174.5M
Diluted EPS	$-0.34	$-0.36	$-0.48	$-0.63	$-0.77

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-25

424B52026-06-25

424B52026-06-24

8-K2026-06-22

42026-06-02

42026-06-02

42026-06-02

42026-06-02

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on TSHA

Search Taysha Gene Therapies, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.